LRMR · Larimar Therapeutics, Inc.
The AI's read
The FDA said the existing data could support review and may consider skin frataxin levels as a measure. This makes a review path clearer, but approval is not assured. Larimar's quarterly loss narrowed to $31.1 million from $47.7 million, mostly because drug-making costs fell. Its $128.7 million in cash is projected to last into late Q2 2027, before the targeted Q3 2027 launch, if approved.